Cambridge, United Kingdom · Founded 2020 · Privately Held (backing)
Developer of a biotechnology platform designed to develop tools for large-scale analysis of genetic variations and gene function. Enhanced Genomics is based in Cambridge, United Kingdom and was founded in 2020. Its last reported valuation was $28.1 million in Sep 2025. It has raised $21.8 million.
Last reported valuation
$28.1M
Oct 2026
Priced at
—
Total raised
$21.8M
Last round
—
No prints on record
No secondary trades in Enhanced Genomics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Enhanced Genomics with a free account
·Watch Enhanced Genomics: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Enhanced Genomics stock.
